Orum Therapeutics
Clinical stage biotechnology company pioneering a novel class of protein degraders
Clinical stage biotechnology company pioneering a novel class of protein degraders
Orum Therapeutics is a clinical stage biotechnology company with a pioneering approach to developing a novel class of protein degraders. Their TPD² and TPS² approach enables the targeted protein degradation and stabilization for cell-specific delivery, particularly in the realm of oncology. Established in 2016, the company has garnered significant attention with its recent $54.00M Series B investment on 23 June 2021. The investment was led by a consortium of prominent investors including InterVest Co., KB Investments, DS Asset Management, IMM Investment, KDB Investment, NH Investment & Securities, Aion Investment Management, KDB Capital, Atinum Partners, and KDB Industrial Bank. With headquarters in Lexington, MA, USA and Daejeon, South Korea, Orum Therapeutics operates at the intersection of biotechnology and health care, positioning itself as an innovative player in the quest for improved patient outcomes in the oncology space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $54.00M | 10 |
|
23 Jun 2021 |
| Venture Round | Unknown | - | 01 May 2021 | |
| Series B | $30.00M | - | 17 Jul 2019 | |
| Series A | $8.00M | - | 14 Jun 2017 | |
| Pre Seed Round | Unknown | - | 01 Oct 2016 |
No recent news or press coverage available for Orum Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
